title: High dose rate brachytherapy for oral cancer.
abstract: Brachytherapy results in better dose distribution compared with other treatments because of steep dose reduction in the surrounding normal tissues. Excellent local control rates and acceptable side effects have been demonstrated with brachytherapy as a sole treatment modality, a postoperative method, and a method of reirradiation. Low-dose-rate (LDR) brachytherapy has been employed worldwide for its superior outcome. With the advent of technology, high-dose-rate (HDR) brachytherapy has enabled health care providers to avoid radiation exposure. This therapy has been used for treating many types of cancer such as gynecological cancer, breast cancer, and prostate cancer. However, LDR and pulsed-dose-rate interstitial brachytherapies have been mainstays for head and neck cancer. HDR brachytherapy has not become widely used in the radiotherapy community for treating head and neck cancer because of lack of experience and biological concerns. On the other hand, because HDR brachytherapy is less time-consuming, treatment can occasionally be administered on an outpatient basis. For the convenience and safety of patients and medical staff, HDR brachytherapy should be explored. To enhance the role of this therapy in treatment of head and neck lesions, we have reviewed its outcomes with oral cancer, including Phase I/II to Phase III studies, evaluating this technique in terms of safety and efficacy. In particular, our studies have shown that superficial tumors can be treated using a non-invasive mold technique on an outpatient basis without adverse reactions. The next generation of image-guided brachytherapy using HDR has been discussed. In conclusion, although concrete evidence is yet to be produced with a sophisticated study in a reproducible manner, HDR brachytherapy remains an important option for treatment of oral cancer.
authors.affiliation: Department of Radiology, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan. hideya10@hotmail.com
authors.forename: Hideya
authors.initials: H
authors.lastname: Yamazaki
authors.forename: Ken
authors.initials: K
authors.lastname: Yoshida
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Yoshioka
authors.forename: Kimishige
authors.initials: K
authors.lastname: Shimizutani
authors.forename: Souhei
authors.initials: S
authors.lastname: Furukawa
authors.forename: Masahiko
authors.initials: M
authors.lastname: Koizumi
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Ogawa
mesh_terms: D001918:Brachytherapy / Q000401:mortality* / Q000706:statistics & numerical data*; D015897:Comorbidity; D019317:Evidence-Based Medicine; D006801:Humans; D009062:Mouth Neoplasms / Q000401:mortality* / Q000532:radiotherapy*; D015995:Prevalence; D011832:Radiation Injuries / Q000401:mortality*; D011879:Radiotherapy Dosage; D018570:Risk Assessment; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome